standard protocols should be established for treating eligible stroke patients with tissue plasminogen activator (tpa) (recommendation class i, level of evidence b). the iranian standard protocol of intravenous thrombolysis with recombinant tissue plasminogen activator (ivttpa) is the best possible and easy to use method for performing intravenous thrombolysis in iran. this protocol overcomes p...

objective: to evaluate the efficacy and safety of intravenous and catheter directed thrombolysis by recombinant tissue plasminogen activator (alteplase) in the patients with non-traumatic acute limb ischemia (ali). methods: this was a randomized clinical trial being performed between 2009 and 2011 in mashhad university of medical sciences. we included those patients who were<75 years, with symp...

Objectives This study examined the neurologists' perspective toward intravenous thrombolysis for the treatment of acute ischemic stroke and the influencing factors in a Chinese Province. Methods A cross-sectional study was conducted from 1 October 2014 to 31 January 2015. A total of 719 neurologists from 66 hospitals in Hubei Province were included. A questionnaire was designed, and multivari...

Thrombolysis for stroke is being used in some developing countries. This study was designed to evaluate the problems of thrombolysis therapy in Iran. During January-July 2008, all patients with ischemic stroke admitted to Ghaem Hospital, Mashhad, northeast Iran, were enrolled in a prospective observational study. Ghaem Hospital is a tertiary care hospital that includes infrastructure for thromb...

BACKGROUND Despite stroke's high prevalence in the elderly, intravenous thrombolysis is licensed in Europe only for patients younger than 80 years old. We aimed to compare the functional outcomes and complication rates in patients older versus younger than 80 years old treated with intravenous thrombolysis. METHODS A retrospective observational study of patients who received intravenous throm...

BACKGROUND AND PURPOSE In patients with ischemic stroke, randomized trials showed a better functional outcome after endovascular therapy with new-generation thrombectomy devices compared with medical treatment, including intravenous thrombolysis. However, effects on mortality and the generalizability of results to routine clinical practice are uncertain. METHODS In a prospective observational...

Recent successful clinical trials of endovascular thrombectomy for large artery ischaemic stroke have established the value of this treatment modality as an adjunct to intravenous thrombolysis, not as an alternative: thrombectomy delivery was undertaken in the context of highly efficient networks for acute thrombolysis delivery and the great majority of patients received IV thrombolytic drug tr...

BACKGROUND AND PURPOSE Intravenous thrombolysis with tissue plasminogen activator is standard treatment in acute stroke today. The benefit of endovascular treatment has been questioned. Recently, studies evaluating endovascular treatment and intravenous thrombolysis compared with intravenous thrombolysis alone, have reported improved outcome for the intervention group. The aim of this study was...

thrombolysis for stroke is being used in some developing countries. this study was designed to evaluate the problems of thrombolysis therapy in iran. during january-july 2008, all patients with ischemic stroke admitted to ghaem hospital, mashhad, northeast iran, were enrolled in a prospective observational study. ghaem hospital is a tertiary care hospital that includes infrastructure for thromb...

BACKGROUND Symptomatic intracranial hemorrhage (SICH) is a devastating complication of intravenous thrombolysis treatment that is associated with high mortality. Clinical trials, stroke registries and cohort studies employ different case definitions to identify stroke patients with SICH following intravenous thrombolysis. We systematically reviewed the reported rates of SICH following intraveno...